文献速递银屑病与炎症性皮肤病

免疫调节剂对免疫介导炎症性疾病患者接种BNT162b2和AZD1222疫苗后血清转化的影响:一项前瞻性队列研究

The effect of immunomodulators on seroconversion after BNT162b2 and AZD1222 vaccines in patients with immune-mediated inflammatory diseases: a prospective cohort study.
PubMed 文献 · Br J Dermatol · 2023-01-01

该前瞻性队列研究纳入接受生物制剂和/或非生物制剂治疗的免疫介导炎症性疾病患者,采集第一剂或第二剂BNT162b2或AZD1222疫苗接种后的血清样本。结果显示,与生物制剂单药治疗相比,非生物制剂治疗(调整OR 0.29,95%CI 0.12-0.69)及非生物制剂联合生物制剂治疗(调整OR 0.14,95%CI 0.045-0.45)与血清转化降低相关;第二剂后未血清转化与接受利妥昔单抗相关。

要点

  • 第一剂疫苗后17.6%(n=34)的参与者未发生血清转化。
  • 与生物制剂单药治疗相比,非生物制剂治疗(调整OR 0.29,95%CI 0.12-0.69)及联合治疗(调整OR 0.14,95%CI 0.045-0.45)与血清转化降低相关。
  • 第二剂疫苗后1.6%的参与者未血清转化,接受利妥昔单抗者(4例中3例)与接受其他治疗者(308例中2例)相比,未血清转化相关(P < 0.001)。

核心结论

  • 非生物制剂治疗,尤其是甲氨蝶呤,与免疫介导炎症性疾病患者接种两剂BNT162b2或AZD1222疫苗后血清转化受损相关。

研究设计与样本

  • 前瞻性队列研究,纳入接受生物制剂和/或非生物制剂治疗的银屑病、银屑病关节炎、类风湿关节炎、炎症性肠病或系统性红斑狼疮患者,采集第一剂或第二剂BNT162b2或AZD1222疫苗接种后的血清样本。
  • 排除既往COVID-19者后,第一剂后样本来自193名参与者,第二剂后样本来自312名参与者。
  • 血清转化定义为Roche Elecsys® Anti-SARS-CoV-2 S(刺突蛋白亚基S1/受体结合域)免疫测定阳性(≥ 0.8 U mL-1)。
  • 采用逻辑回归评估免疫调节剂暴露与血清转化的关联,调整年龄和性别。

主要发现

  • 第一剂疫苗后,17.6%(n = 34)的参与者未发生血清转化。
  • 与生物制剂单药治疗相比,非生物制剂治疗(调整OR 0.29,95%CI 0.12-0.69)或非生物制剂联合生物制剂治疗(调整OR 0.14,95%CI 0.045-0.45)与血清转化降低相关。
  • 亚组分析显示,与肿瘤坏死因子-α抑制剂单药治疗相比,甲氨蝶呤治疗(调整OR 0.097,95%CI 0.19-0.49)或泼尼松龙治疗(调整OR 0.044,95%CI 0.002-1.00)与血清转化降低相关。
  • 接受利妥昔单抗的参与者(n < 5)在第一剂疫苗后均未发生血清转化。
  • 第二剂疫苗后,1.6%的参与者未发生血清转化;未血清转化与接受利妥昔单抗(4例中3例)相比接受其他治疗(308例中2例)相关(P < 0.001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Biologic and nonbiologic immunomodulators, used to treat immune-mediated inflammatory diseases (IMIDs), could impair the immune response to COVID-19 vaccines and thus vaccine effectiveness. OBJECTIVES: Our objective was to investigate the association between biologic and nonbiologic immunomodulators and seroconversion following the first and second dose of COVID-19 vaccines in patients with IMIDs. METHODS: Serum samples were collected following the first or second dose of the BNT162b2 or AZD1222 vaccines from patients receiving biologic and/or nonbiologic immunomodulators for one or more of psoriasis, psoriatic arthritis, rheumatoid arthritis, inflammatory bowel disease or systemic lupus erythematosus. Seroconversion was defined as a positive Roche Elecsys® Anti-SARS-CoV-2 S (spike protein subunit S1/receptor binding domain) immunoassay (≥ 0.8 U mL-1). Association between immunomodulator exposure and seroconversion was assessed using logistic regression, adjusting for age and sex. RESULTS: After excluding those with prior COVID-19, post-first vaccine dose samples from 193 participants and post-second dose samples from 312 participants were included in the analysis. Following the first vaccine dose, 17.6% (n = 34) of participants did not seroconvert. Seroconversion was reduced for those on nonbiologic [adjusted odds ratio (OR) 0.29, 95% confidence interval (CI) 0.12-0.69] or combined nonbiologic and biologic treatment (adjusted OR 0.14, 95% CI 0.045-0.45) compared with those on biologic monotherapy. Subgroup analysis demonstrated reduced odds of seroconversion in those on methotrexate (adjusted OR 0.097, 95% CI 0.19-0.49) or prednisolone treatment (adjusted OR 0.044, 95% CI 0.002-1.00) relative to tumour necrosis factor-α inhibitor monotherapy. No participants receiving rituximab (n < 5) seroconverted after the first vaccine dose. Following the second vaccine dose, 1.6% of all participants did not seroconvert. Non-seroconversion was associated with receiving rituximab (n = 3 of 4) compared with those receiving other therapies (n = 2 of 308, P < 0.001). Post hoc analyses demonstrated that non-seroconversion was associated with age [adjusted OR 0.18, 95% CI 0.037-0.93 for those aged 60 years and over (reference category age 18-39 years)], but not sex, ethnicity or vaccine type. CONCLUSIONS: Treatment with nonbiologics, particularly methotrexate, is associated with impaired seroconversion following two BNT162b2 or AZD1222 vaccine doses, in patients with IMIDs. These findings are consistent with those of other published studies. While this could indicate reduced protection against COVID-19, the immunological parameters that correlate most closely with vaccine effectiveness need to be defined to reach this conclusion.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Al-Janabi A, Ra A, Littlewood Z, et al. The effect of immunomodulators on seroconversion after BNT162b2 and AZD1222 vaccines in patients with immune-mediated inflammatory diseases: a prospective cohort study. Br J Dermatol. 2023. PMID: 36695406. doi:10.1093/bjd/ljac109

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。